FDC Limited’s Q4 FY 2024 PAT Jumps 50.9% to ₹46 Crore

On May 30, 2024, FDC Limited, one of the leading fully integrated pharmaceutical companies in India, announced their financial performance for the quarter ended March 2024 and the financial year 2024.

Financial Performance in Q4 FY 2024

In the quarter ended March 2024, FDC Limited’s operating revenue was ₹462 crore, which is up by 6.3% compared to ₹435 crore in Q4 FY 2023. The company’s EBITDA was ₹56 crore, which grew by 15.1% from ₹49 crore during the same period in FY 2023.

The company reported a Profit After Tax (PAT) of ₹46 crore in Q4 FY 2024, which is 50.9% higher than ₹31 crore in Q4 FY 2023.

Financial Performance in FY 2024

In FY 2024, FDC Limited’s operating revenue was ₹1,943 crore, which is up by 8.9% compared to ₹1,784 crore in FY 2023. The company’s EBITDA was ₹339 crore, which grew by 34.9% from ₹251 crore in FY 2023.

The company reported a PAT of ₹305 crore in FY 2024, which is 57.4% higher than ₹194 crore in FY 2023.

Sales Performance

The sale of Domestic-Branded formulations for Q4 FY24 stood at ₹358 crores, registering a growth of 6.1% YoY. For FY24, sales were at ₹1,555 crores, a growth of 8.0% over the same period last year. The Domestic-Branded Formulation business accounted for 79% for the quarter and 80% for FY24.

Export Formulations Business

The company’s revenue in the export formulation business in Q4 is ₹73 crore, marginally down by 3.1% over YoY and ₹288 crore for FY24, up by 12.9% over the same period last year. The export formulation business accounted for 15% of consolidated revenue for the FY24.

Commenting on the results, the company stated, “We are delighted to report consistent growth momentum in revenue both in the domestic as well as the international market during Q4 and for the fiscal year FY24. Growth in the Domestic Formulation business is majorly contributed by our flagship brands Electral, Zifi, Enerzal and Zifi-O. The International Formulation business continues to show healthy traction both in the US and ROW markets. During the fiscal year FY24, the consolidated revenue in the international formulation business grew by 12% with a revenue of ₹288 crore. The API business has also performed well with strag double-digit growth.”

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.